Marcy l'Étoile, France - July 22, 2010.
Sales: €651 million
- Up 6% at constant exchange rates and scope of consolidation
- Strong performance of clinical and industrial microbiology as well as VIDAS®
- Robust growth in emerging countries
- 2010 operating margin objective confirmed
bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the six months ended June 30, 2010.
Net sales for the first half of 2010 reached €651 million, a 6% year-on-year increase at constant exchange rates and scope of consolidation (like-for-like).
Download
- Filename
- bmx_pr_sales_q2_2010_en2_0.pdf
- Size
- 126 KB
- Format
- application/pdf